Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

A University of Missouri scientist develops a cancer “flashlight” that helps identify which patients are most likely to respond to targeted therapies. To better understand which patients may respond ...

New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

A team of Australian researchers have developed a new targeted therapeutic approach that could improve treatment for ...

TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

The TellDx CTC iChip platform enables high-efficiency isolation of intact circulating tumor cells without reliance on cell size or epithelial markers. This unbiased approach is particularly well ...

Researchers at University of California San Diego have identified a previously unrecognized treatment target for ...

Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...